2. Search Result
Search Result
Results for "

Y1 receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Fluorescent Dye

1

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-101704A
    Y1 receptor antagonist 1 formic

    H 409-22 isomer formic

    		 Neurokinin Receptor Cardiovascular Disease Neurological Disease
    Y1 receptor antagonist 1 (H 409-22 isomer) formic (Example 4) is a neuropeptide Y1 receptor antagonist. Y1 receptor antagonist 1 can be used for the study of cardiovascular diseases, such as vasoconstriction .
    Y1 receptor antagonist 1 formic
  • HY-107726
    BIBP3226 TFA

    		Neuropeptide Y Receptor Neurological Disease
    BIBP3226 TFA is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with Kis of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. BIBP3226 TFA displays anxiogenic-like effect .
    BIBP3226 TFA
  • HY-107725
    BIBO3304
    2 Publications Verification

    		 Neuropeptide Y Receptor Metabolic Disease
    BIBO3304 is a potent, orally active, and selective neuropeptide Y (NPY) Y1 receptor antagonist, with subnanomolar affinity for both the human and the rat Y1 receptor (IC50=0.38 and 0.72 nM, respectively) .
    BIBO3304
  • HY-107723
    CGP71683 hydrochloride

    CGP71683A

    		 Neuropeptide Y Receptor Neurological Disease Endocrinology
    CGP71683 hydrochloride is a competitive neuropeptide Y5 receptor antagonist with a Ki of 1.3 nM, and shows no obvious activity at Y1 receptor (Ki, >4000 nM) and Y2 receptor (Ki, 200 nM) in cell membranes.
    CGP71683 hydrochloride
  • HY-101704
    Y1 receptor antagonist 1

    H 409-22 (isomer)

    		 Neurokinin Receptor Cardiovascular Disease Neurological Disease
    Y1 receptor antagonist 1 (H 409-22 isomer) (Example 4) is a neuropeptide Y1 receptor antagonist. Y1 receptor antagonist 1 can be used for the study of cardiovascular diseases, such as vasoconstriction .
    Y1 receptor antagonist 1
  • HY-144603
    Neuropeptide Y Y1 receptor antagonist 1

    		Neuropeptide Y Receptor Neurological Disease
    Neuropeptide Y Y1 receptor antagonist 1 (compound 39), a fluorescent probe, is a potent antagonist of neuropeptide Y Y 1 receptor (Y 1R), with a Ki of 0.19 nM .
    Neuropeptide Y Y1 receptor antagonist 1
  • HY-107726A
    BIBP3226

    		Neuropeptide Y Receptor Neurological Disease
    BIBP3226 is a potent and selective neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptor antagonist, with Kis of 1.1, 79, and 108 nM for rNPY Y1, hNPFF2, and rNPFF, respectively. BIBP3226 displays anxiogenic-like effect .
    BIBP3226
  • HY-107727
    BMS-193885 L-Lactic acid

    		Neuropeptide Y Receptor Neurological Disease
    BMS-193885 (L-Lactic acid) is a potent, selective, and brain-penetrant neuropeptide Y1 receptor antagonist. BMS-193885 has a Ki value of 3.3 nM for the neuropeptide Y1 receptor, competitively acts on the neuropeptide Y binding site, and can reduce food intake and body weight through central Y1 inhibition .
    BMS-193885 L-Lactic acid
  • HY-120096
    BIBO3304 free base

    		Neuropeptide Y Receptor Neurological Disease
    BIBO3304 free base is a nonpeptide neuropeptide Y Y1 receptor antagonist. BIBO3304 free base displays subnanomolar affinity for both the human and the rat Y1 receptor, with IC50 values of 0.38 nM and 0.72 nM, respectively. BIBO3304 free base significantly inhibits food intake induced by application of NPY or by fasting .
    BIBO3304 free base
  • HY-107725A
    BIBO3304 diTFA

    		Wnt Neuropeptide Y Receptor Metabolic Disease
    BIBO3304 (diTFA) is an orally effective and selective neuropeptide Y (NPY) Y1 receptor antagonist. BIBO3304 (diTFA) has a high affinity for both human and rat Y1 receptors, with IC50 values of 0.38 and 0.72 nM, respectively. BIBO3304 (diTFA) promotes bone-tendon healing through the Wnt/β-catenin signaling pathway .
    BIBO3304 diTFA
  • HY-P1327
    BVD 10

    		Neuropeptide Y Receptor Neurological Disease
    BVD 10, a neuropeptide Y (NPY) analogue peptide, is a highly selective NPY Y1 receptor antagonist. BVD10 significantly prevents NPY-induced glutamate increase. BVD 10 can be used for seizure research .
    BVD 10
  • HY-120619
    BMS-193885

    		Neuropeptide Y Receptor Neurological Disease Endocrinology
    BMS-193885 is a selective neuropeptide Y1 receptor antagonist (Ki=3.3 nM) that competitively blocks the receptor to inhibit NPY-mediated appetite regulation signaling pathways, reduce food intake and inhibit weight gain. BMS-193885 has good blood-brain barrier penetration and is mainly used in the study of obesity and related metabolic diseases .
    BMS-193885
  • HY-107732
    JNJ-5207787

    		Neuropeptide Y Receptor Neurological Disease
    JNJ-5207787 is a nonpeptidic, selective and penetrate the blood-brain barrier neuropeptide Y Y2 receptor (Y2) antagonist. JNJ-5207787 inhibits the binding of peptide YY (PYY) with pIC50s of 7.0 and 7.1 for human Y2 receptor and rat Y2 receptor, respectively. JNJ-5207787 is >100-fold selective versus human Y1, Y4, and Y5 receptors .
    JNJ-5207787
  • HY-107479
    (R)-JNJ-31020028

    		Neuropeptide Y Receptor Neurological Disease
    (R)-JNJ-31020028 is a high affinity, selective brain penetrant neuropeptide Y Y2 receptor antagonist, with pIC50 values of 8.07, 8.22 and 8.21 for human, rat, and mouse Y2 receptor, respectively. (R)-JNJ-31020028 shows >100-fold selective versus human Y1, Y4, and Y5 receptors. (R)-JNJ-31020028 has antidepressant like effects .
    (R)-JNJ-31020028
  • HY-174126
    P2Y1 antagonist 2

    		P2Y Receptor Cardiovascular Disease
    P2Y1 antagonist 2 (Compound 19) is a P2Y1 receptor antagonist (IC50: 0.49 μM). P2Y1 antagonist 2 has significant antiplatelet aggregation activity and exerts its effects by inhibiting P2Y1 receptor. P2Y1 antagonist 2 can upregulate nuclear Nrf2 protein levels, exhibit neuroprotective effects, and resist oxidative stress damage. P2Y1 antagonist 2 can effectively reduce cerebral infarction area and improve neurobehavioral function, and can be used in the study of ischemic stroke .
    P2Y1 antagonist 2
  • HY-13831
    BPTU

    BMS-646786

    		 P2Y Receptor Neurological Disease Cancer
    BPTU (BMS-646786) is a non-nucleotide P2Y1 receptor allosteric antagonist with antithrombotic activity. BPTU is able to block the P2Y1 receptor located at the neuromuscular junction of the gastrointestinal tract .
    BPTU
  • HY-108662
    PIT

    2,2'-Pyridylisatogen tosylate

    		 P2Y Receptor Inflammation/Immunology Cancer
    PIT (2,2'-Pyridylisatogen tosylate) is a selective and non-competitive antagonist of P2Y1 receptor with an IC50 value of 0.14 μM for human P2Y1 receptor. PIT antagonizes P2Y1 receptor signaling without affecting nucleotide binding. PIT is an irreversible antagonist of responses to ATP at metabotropic purinoceptors (of the P2Y family) in some smooth muscles. PIT can be used for the research of chronic bronchitis and asthma .
    PIT
  • HY-115273
    MRS-2179

    		P2Y Receptor Others
    MRS-2179 is a selective and competitive antagonist for P2Y1 receptor, with KB of 0.177 μM .
    MRS-2179
  • HY-108658
    MRS2500 tetraammonium

    		P2Y Receptor Cardiovascular Disease
    MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity .
    MRS2500 tetraammonium
  • HY-101308
    MRS2179 tetrasodium

    		P2Y Receptor Cardiovascular Disease
    MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium inhibits platelet aggregation .
    MRS2179 tetrasodium
  • HY-101308A
    MRS2179 tetrasodium hydrate
    2 Publications Verification

    		 P2Y Receptor Cardiovascular Disease
    MRS2179 tetrasodium hydrate is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium hydrate is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors . MRS2179 tetrasodium hydrate inhibits platelet aggregation .
    MRS2179 tetrasodium hydrate
  • HY-D1199
    Blue FPG-A trisodium

    		P2X Receptor P2Y Receptor Inflammation/Immunology
    Blue FPG-A trisodium is a selective antagonist of P2X1 receptor and P2Y1 receptor with IC50 values of 35.5 μM and 2.6 μM, respectively. Blue FPG-A trisodium is a structural isomer of the components of Reactive Blue 2 (RB2) .
    Blue FPG-A trisodium
  • HY-119145
    MRS2496

    		P2Y Receptor Cardiovascular Disease
    MRS2496 is a selective P2Y1 receptor antagonist with an IC50 value of 1.5 μM, exhibiting antiplatelet aggregation activity. MRS2496 can be used in the research of antiplatelet aggregation and blood-related diseases .
    MRS2496
  • HY-N7740
    Adenosine 2',5'-diphosphate sodium

    		P2Y Receptor Endogenous Metabolite Others
    Adenosine 2',5'-diphosphate sodium is a competitive P2Y1 antagonist. Adenosine 2',5'-diphosphate sodium exhibits non-selective antagonism at recombinant and human platelet P2X1 receptors .
    Adenosine 2',5'-diphosphate sodium
  • HY-13104
    MRS 2578
    Maximum Cited Publications
    8 Publications Verification

    		 P2Y Receptor Apoptosis Cardiovascular Disease
    MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors .
    MRS 2578
  • HY-113723
    MRS2298

    		P2Y Receptor Cardiovascular Disease
    MRS2298? is a potent acyclic P2Y1 receptor antagonist with a Ki of 29.6 nM. MRS2298 inhibits the ADP-induced aggregation of human platelets with an IC50 of 62.8 nM. MRS2298 inhibits Ca 2+ rise in platelets with an IC50 of 810 nM .
    MRS2298
  • HY-108657
    MRS2279

    		P2Y Receptor Neurological Disease
    MRS2279 is a selective and high affinity P2Y1 receptor antagonist, with a Ki of 2.5 nM and an IC50 of 51.6 nM. MRS2279 competitively inhibits ADP-promoted platelet aggregation with an apparent affnity (pKB=8.05) .
    MRS2279
  • HY-110322A
    PPTN
    2 Publications Verification

    		 P2Y Receptor Inflammation/Immunology
    PPTN is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
    PPTN
  • HY-110322
    PPTN hydrochloride
    2 Publications Verification

    		 P2Y Receptor Inflammation/Immunology
    PPTN hydrochloride is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN hydrochloride exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and anti-immune activity .
    PPTN hydrochloride
  • HY-103055
    PPTN mesylate

    		P2Y Receptor Inflammation/Immunology
    PPTN mesylate is a potent, high-affinity, competitive and highly selective P2Y14 receptor antagonist with a KB value of 434 pM. PPTN mesylate exhibits no agonist or antagonist effect at the P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, or P2Y13 receptors. Anti-inflammatory and immune activity .
    PPTN mesylate
  • HY-108657A
    MRS2279 diammonium
    1 Publications Verification

    		 P2Y Receptor Neurological Disease
    MRS2279 diammonium is a selective and high affinity P2Y1 receptor antagonist, with a Ki value of 2.5 nM and an IC50 value of 51.6 nM. MRS2279 diammonium competitively inhibits ADP-promoted platelet aggregation with an pKb value of 8.05 .
    MRS2279 diammonium
  • HY-13104R
    MRS 2578 (Standard)

    		P2Y Receptor Apoptosis Cardiovascular Disease
    MRS 2578 (Standard) is the analytical standard of MRS 2578. This product is intended for research and analytical applications. MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat). MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors .
    MRS 2578 (Standard)
  • HY-137955
    MRS 2211 sodium hydrate

    		P2Y Receptor Cardiovascular Disease Others Neurological Disease
    MRS 2211 sodium hydrate is a competitive P2Y13 receptor antagonist (pIC50= 5.97). MRS 2211 sodium hydrate is highly selective to the P2Y13 receptor, showing more than 20-fold selectivity compared to the P2Y1 and P2Y12 receptors. MRS 2211 sodium hydrate can be used to further investigate the role of the P2Y13 receptor in different physiological and pathological processes, such as its function in blood cells, the nervous system and the immune system .
    MRS 2211 sodium hydrate
  • HY-108656
    MRS2365

    		P2Y Receptor Arrestin Cardiovascular Disease
    MRS2365 is a potent and selective P2Y1 receptor (EC50=0.4 nM) /[ 35S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC50 of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors .
    MRS2365
  • HY-137610A
    TNP-ATP tetrasodium

    		P2X Receptor P2Y Receptor Neurological Disease
    TNP-ATP is an antagonist of purinergic P2Y1, P2X3, and P2X2/3 receptors (IC50 = 6, 0.9, and 7 nM, respectively, in HEK293 cells expressing human receptors). TNP-ATP reduces acetate-induced calcium flux in 1321N1 cells expressing P2X3 and P2X2/3 receptors (IC50 = 100 and 62 nM, respectively). TNP-ATP dose-dependently attenuates acetate-induced abdominal contractions in a mouse visceral pain model (ED50 = 6.35 µmol/kg) [1][2].
    TNP-ATP tetrasodium
  • HY-137325A
    2-Chloro-ATP sodium

    		Calcium Channel Metabolic Disease
    2-Chloro-ATP sodium (2-Chloro ATP) is an adenine nucleotide and an analog of ATP. It is an antagonist of the purinergic P2Y1 receptor and inhibits intracellular calcium mobilization induced by ADP (HY-W010918) in Jurkat cells expressing the human receptor (Ki=2.3 μM). 2-Chloro-ATP sodium is an agonist of the purinergic P2X receptor and induces inward currents in HEK293 cells expressing human bladder smooth muscle or rat PC12 forms of the receptor (EC50=0.5 and 2.5 μM). 2-Chloro-ATP sodium induces relaxation of precontracted guinea pig cecal strips in a concentration-dependent manner. 2-Chloro-ATP sodium has been used to study the substrate specificity of cyclic nucleotide-dependent protein kinases such as protein kinase A (PKA) and PKG.
    2-Chloro-ATP sodium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: